Divi's Laboratories Past Earnings Performance
Past criteria checks 5/6
Divi's Laboratories has been growing earnings at an average annual rate of 3.8%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 8.7% per year. Divi's Laboratories's return on equity is 12.3%, and it has net margins of 20.5%.
Key information
3.8%
Earnings growth rate
3.8%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | 8.7% |
| Return on equity | 12.3% |
| Net Margin | 20.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts
Aug 06
The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts
Jul 19Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price
Apr 19Divi's Laboratories Limited (NSE:DIVISLAB) Not Flying Under The Radar
Dec 27Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00
Aug 04Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00
Jul 20Divi's Laboratories (NSE:DIVISLAB) Has Announced A Dividend Of ₹30.00
Jul 06Is Now The Time To Put Divi's Laboratories (NSE:DIVISLAB) On Your Watchlist?
Nov 08Divi's Laboratories (NSE:DIVISLAB) Is Increasing Its Dividend To ₹30.00
Aug 04Divi's Laboratories' (NSE:DIVISLAB) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 21Divi's Laboratories (NSE:DIVISLAB) Will Pay A Larger Dividend Than Last Year At ₹30.00
Jul 07Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Might Deserve Your Attention Today
Jul 03Does Divi's Laboratories (NSE:DIVISLAB) Deserve A Spot On Your Watchlist?
Apr 03Should You Be Adding Divi's Laboratories (NSE:DIVISLAB) To Your Watchlist Today?
Dec 23With EPS Growth And More, Divi's Laboratories (NSE:DIVISLAB) Is Interesting
Sep 02Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Is Well Worth Watching
Mar 25Do Institutions Own Divi's Laboratories Limited (NSE:DIVISLAB) Shares?
Mar 10Revenue & Expenses Breakdown
How Divi's Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 81,850 | 16,740 | 11,350 | 0 |
| 31 Mar 24 | 78,450 | 16,000 | 11,060 | 0 |
| 31 Dec 23 | 74,926 | 13,834 | 10,670 | 0 |
| 30 Sep 23 | 73,456 | 13,314 | 10,380 | 0 |
| 30 Jun 23 | 72,906 | 14,774 | 10,040 | 0 |
| 31 Mar 23 | 77,670 | 18,240 | 9,870 | 0 |
| 31 Dec 22 | 83,353 | 23,971 | 9,851 | 0 |
| 30 Sep 22 | 91,208 | 29,925 | 9,908 | 0 |
| 30 Jun 22 | 92,538 | 31,054 | 9,827 | 0 |
| 31 Mar 22 | 89,599 | 29,605 | 9,571 | 0 |
| 31 Dec 21 | 82,297 | 25,678 | 9,154 | 0 |
| 30 Sep 21 | 74,379 | 21,362 | 9,044 | 0 |
| 30 Jun 21 | 71,996 | 20,493 | 8,736 | 0 |
| 31 Mar 21 | 69,695 | 19,843 | 8,367 | 0 |
| 31 Dec 20 | 65,710 | 18,705 | 7,950 | 0 |
| 30 Sep 20 | 62,658 | 17,590 | 7,179 | 0 |
| 30 Jun 20 | 59,620 | 15,962 | 6,641 | 0 |
| 31 Mar 20 | 53,945 | 13,765 | 6,317 | 0 |
| 31 Dec 19 | 52,719 | 12,803 | 5,995 | 0 |
| 30 Sep 19 | 52,356 | 13,106 | 5,824 | 0 |
| 30 Jun 19 | 51,139 | 13,575 | 5,694 | 0 |
| 31 Mar 19 | 49,463 | 13,527 | 5,525 | 0 |
| 31 Mar 18 | 38,915 | 8,770 | 4,651 | 0 |
| 31 Mar 17 | 40,643 | 10,604 | 5,090 | 0 |
| 31 Mar 16 | 37,764 | 11,258 | 3,669 | 277 |
| 31 Mar 15 | 31,049 | 8,515 | 2,927 | 252 |
| 31 Mar 14 | 25,267 | 7,733 | 3,173 | 229 |
Quality Earnings: DIVISLAB has high quality earnings.
Growing Profit Margin: DIVISLAB's current net profit margins (20.5%) are higher than last year (20.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DIVISLAB's earnings have grown by 3.8% per year over the past 5 years.
Accelerating Growth: DIVISLAB's earnings growth over the past year (13.3%) exceeds its 5-year average (3.8% per year).
Earnings vs Industry: DIVISLAB earnings growth over the past year (13.3%) exceeded the Life Sciences industry 13.3%.
Return on Equity
High ROE: DIVISLAB's Return on Equity (12.3%) is considered low.